FBXO-25’s Viability of a Prognostic Indicator of Effective Cancer Treatment
AJAS · 2017 Biomedical and Health Sciences (inferred)
Overview
Tumors occur when cells proliferate because of problems within a cell’s apoptotic processes. Colorectal adenocarcinoma, which accounts for 95% of all colon cancers, demonstrates an aberrant PRKCD-FBXO-25-HAX-1 axis where emerging research has shown that the PRKCD protein contributes to apoptosis, FBXO-25 is considered a tumor suppressor and, HAX-1 a proto-oncogene. The aberrant HAX-1 axis is anti-apoptotic, contributing to increased resistance to chemotherapeutic drugs. A study of the effect of FBXO-25 protein expression on HAX-1 activity is of interest in the treatment of this aggressive cancer, as HAX-1 has been suggested a substrate of FBXO-25. In the research reported, both cell viability and protein expression were measured through MTS assay and indirect ELISA in a colorectal adenocarcinoma cell line, HT29. Two groups of colorectal adenocarcinoma cells were used; one with FBXO-25 downregulated through interference RNA and another with constitutive FBXO-25 protein expression. FBXO-25’s effect on chemotherapeutic resistance was measured by treating both cell lines with varying concentrations of cisplatin ranging from 50µM – 3.125 µM for 24h. Downregulation of FBXO-25 rendered increased cellular viability (p<0.05) due to an increase in HAX-1 protein expression with increased chemotherapeutic resistance. With HAX-1 levels increased due to low FBXO-25 levels, this research suggests that levels of FBXO-25 can be used as a prognostic indicator in colorectal cancer.
Competition history
- AJAS 2017
Related projects
ISEF · 2022
The Roles of Activin-A and Its Antagonists in Early and Late Stages of Colon Cancer: In vitro Study
AJAS · 2025
Relationship Between FBXO45 and Tumor Suppressor PAR-4 in Cancer
ISEF · 2023
The Effects of APC Loss on Response to Chemotherapy in Ovarian Cancer Cells
ISEF · 2017
The Regulation of ATF4/CHOP by c-Myc in NSAID-induced Chemoprevention
ISEF · 2024
The Impact of Paclitaxel and Doxorubicin on APC Knockout Cells in Breast Cancer
AJAS · 2022
A New Potential Treatment For Colorectal Cancer
ISEF · 2022
What Is the Role of PRPF39 in Cisplatin Treated Cancer Cells?
AJAS · 2025
CDK9-Specific PROTAC 2 Treatment Sensitizes Pancreatic Cancer Cells to Navitoclax
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: AAAS Annual Meeting (Confex) / American Junior Academy of Science